Clinical Trials Logo

Lung Cancer, Small Cell clinical trials

View clinical trials related to Lung Cancer, Small Cell.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05228496 Active, not recruiting - Clinical trials for Lung Cancer, Small Cell

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Start date: March 17, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with sitravatinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive stage small cell lung cancer.

NCT ID: NCT04986670 Active, not recruiting - Clinical trials for Lung Cancer, Non-small Cell

NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer

Start date: November 24, 2020
Phase: N/A
Study type: Interventional

The NutriCare study aims to develop, implement, and evaluate the efficacy of an innovative intervention strategy (medically tailored meals plus nutrition counseling) to integrate nutrition into the standard of care for oncology to improve outcomes of vulnerable patients with lung cancer. The NutriCare study evaluates the efficacy of the intervention on optimizing nutritional status, reducing treatment-related toxicities, and improving the quality of life of patients with lung cancer who are economically disadvantaged, uninsured, racial and ethnic minorities, elderly, and/or rural residents from four major medical centers in diverse regions of the United States (U.S.). There will be two cohorts for NutriCare with cohort 1 recruiting 150 patients completing an 8-month intervention and cohort 2 recruiting 120 patients completing a 6-month intervention.

NCT ID: NCT04660929 Active, not recruiting - Breast Cancer Clinical Trials

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.